Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc. (NASDAQ:BBIO), filed a Form 4 on November 3, 2026, disclosing the sale of 2,000 shares of common stock on October 30, 2026.

Key Highlights

  • Reporting person: Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc.
  • Transaction: Disposition (code S) of 2,000 shares of common stock on October 30, 2026.
  • Sale price: $72.85 per share.
  • Remaining holdings: 120,687 shares of common stock held directly following the transaction.
  • 10b5-1 plan: The sale was effected pursuant to a Rule 10b5-1 sales plan adopted on September 8, 2025.

Details of Maricel Apuli's October 2026 Share Disposal

According to the Form 4 filed with the SEC on November 3, 2026, Maricel Apuli, who serves as Chief Accounting Officer at BridgeBio Pharma, Inc., disposed of 2,000 shares of the company's common stock on October 30, 2026, at a price of $72.85 per share. The filing indicates the transaction code was "S," reflecting an open-market sale. The filing notes that the form was checked to indicate a transaction made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c).

The filing states that the sale was carried out under a Rule 10b5-1 sales plan that Apuli adopted on September 8, 2025. Following the reported transaction, Apuli directly beneficially owns 120,687 shares of BridgeBio Pharma common stock, according to the filing. No derivative securities transactions were reported in Table II of the form.

The Form 4 was filed by one reporting person and was signed by Maricel Apuli on November 3, 2026. BridgeBio Pharma, Inc. is listed on NASDAQ under the ticker symbol BBIO, as stated on the filing's cover page.

What Was Disclosed

The filing disclosed a single open-market sale of 2,000 BridgeBio Pharma common shares by Chief Accounting Officer Maricel Apuli at $72.85 per share on October 30, 2026, executed under a pre-established Rule 10b5-1 plan, leaving her with 120,687 directly held shares.